Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice

Autor: Ermini G., Tosetti C., Zocchi D., Mandreoli M., Caletti M. T., Marchesini G., Balduzzi A., Bandi G., Bassi B., Borghi P., Brini L., Cammarata A., Casadio R., Cau R., Cecchini L., DelVecchio A., DeVicariis M. I., Ehrlich S., Franco L., Ini A., LaFratta V., Maccaferri M., Masi A., Matra A., MazzettiGaito P., Mazzoni G., Monti D., Mori M., Oggianu M., Palasciano M., Paternico A., Perrone F., Pierallini R., Quadrelli S., Rubini S., Salera M., Serio A., Silletti A., Simoncini E., Simoni L., Speziali P., Velona P., Verri A., Zisa D.

Publikováno v: Journal of Endocrinological Investigation. 42:787-796

Aims: Progressive chronic kidney disease represents a dreadful complication of type 2 diabetes mellitus (T2DM). We tested the pattern of use and the renal effects of old glucose-lowering drugs in T2DM patients cared for by Italian general practitione

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9eee20d0f72bf32b3135ca5cc8ee4e6
https://doi.org/10.1007/s40618-018-0983-0

Novel Paired Normal Prostate and Prostate Cancer Model Cell Systems Derived from African American Patients.

Autor: Jung M; Department of Radiation Medicine, Georgetown University School of Medicine, Washington, District of Columbia., Kowalczyk K; Department of Urology, Georgetown University School of Medicine, Washington, District of Columbia.; MedStar Georgetown University Hospital, Washington, District of Columbia., Hankins R; Department of Urology, Georgetown University School of Medicine, Washington, District of Columbia.; MedStar Georgetown University Hospital, Washington, District of Columbia., Bandi G; Department of Urology, Georgetown University School of Medicine, Washington, District of Columbia.; MedStar Georgetown University Hospital, Washington, District of Columbia., Kallakury B; Department of Pathology, Georgetown University School of Medicine, Washington, District of Columbia.; MedStar Georgetown University Hospital, Washington, District of Columbia., Carrasquilla MA; Department of Radiation Medicine, Georgetown University School of Medicine, Washington, District of Columbia.; MedStar Georgetown University Hospital, Washington, District of Columbia., Banerjee PP; Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, District of Columbia., Grindrod S; Shuttle Pharmaceuticals, Inc, Rockville, Maryland., Dritschilo A; Department of Radiation Medicine, Georgetown University School of Medicine, Washington, District of Columbia.; MedStar Georgetown University Hospital, Washington, District of Columbia.; Shuttle Pharmaceuticals, Inc, Rockville, Maryland.

Publikováno v: Cancer research communications [Cancer Res Commun] 2022 Dec 13; Vol. 2 (12), pp. 1617-1625. Date of Electronic Publication: 2022 Dec 13 (Print Publication: 2022).

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer.

Autor: Aghdam N; Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States., Pepin AN; Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States.; George Washington School of Medicine and Health Sciences, Washington, DC, United States., Creswell M; Georgetown University School of Medicine, Washington, DC, United States., Hsieh K; Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States.; Columbia University Valegos College of Physicians and Surgeons, New York, NY, United States., Smith C; Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States., Drescher N; Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States.; Geisinger Commonwealth School of Medicine, Scranton, PA, United States., Danner M; Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States., Ayoob M; Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States., Yung T; Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States., Lei S; Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States., Kumar D; Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham, NC, United States., Collins BT; Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States., Lischalk JW; Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States., Krishnan P; Department of Radiology, Georgetown University Hospital, Washington, DC, United States., Suy S; Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States., Lynch J; Department of Urology, Georgetown University Hospital, Washington, DC, United States., Bandi G; Department of Urology, Georgetown University Hospital, Washington, DC, United States., Hankins RA; Department of Urology, Georgetown University Hospital, Washington, DC, United States., Collins SP; Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2020 Oct 29; Vol. 10, pp. 551491. Date of Electronic Publication: 2020 Oct 29 (Print Publication: 2020).

Discovery of Metabolic Biomarkers Predicting Radiation Therapy Late Effects in Prostate Cancer Patients.

Autor: Cheema AK; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.; Department of Biochemistry, Molecular and Cellular Biology, Georgetown University Medical Center, Washington, DC, USA., Grindrod S; Shuttle Pharmaceuticals Inc, Rockville, MD, USA., Zhong X; Department of Biostatistics and Biomathematics, Georgetown University Medical Center, Washington, DC, USA., Jain S; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Menon SS; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Mehta KY; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Suy S; Department of Radiation Medicine, Medstar-Georgetown University Hospital, Washington, DC, USA., Collins S; Department of Radiation Medicine, Medstar-Georgetown University Hospital, Washington, DC, USA., Wang Y; Department of Biostatistics and Biomathematics, Georgetown University Medical Center, Washington, DC, USA., Timofeeva O; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Bandi G; Department of Urology, Medstar-Georgetown University Hospital, Washington, DC, USA., Pahira J; Department of Urology, Medstar-Georgetown University Hospital, Washington, DC, USA., Kowalczyk K; Department of Urology, Medstar-Georgetown University Hospital, Washington, DC, USA., Lynch J; Department of Urology, Medstar-Georgetown University Hospital, Washington, DC, USA., Dritschilo A; Shuttle Pharmaceuticals Inc, Rockville, MD, USA. dritscha@georgetown.edu.; Department of Radiation Medicine, Medstar-Georgetown University Hospital, Washington, DC, USA. dritscha@georgetown.edu.

Publikováno v: Advances in experimental medicine and biology [Adv Exp Med Biol] 2019; Vol. 1164, pp. 141-150.

Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.

Autor: Amadori M; Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Barone D; Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Scarpi E; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. emanuela.scarpi@irst.emr.it., Oboldi D; Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Amadori E; Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Bandi G; Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Rossi A; Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Ferroni F; Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Ragazzini A; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Casadei Gardini A; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Frassineti GL; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Gavelli G; Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Passardi A; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Publikováno v: European radiology [Eur Radiol] 2018 Jul; Vol. 28 (7), pp. 2969-2978. Date of Electronic Publication: 2018 Feb 07.